Author  
Place of duty  
Title   Àü¸³¼± ¾ç¼º ¹× ¾Ç¼ºÁ¾¾ç¿¡¼­ p53 ÀÇ ¹ß°ß ( Expression of p53 in the Benign and Malignant Tumor of Prostate )
Publicationinfo   1994 Jan; 026(05): 793-801.
Key_word   Prostatic carcinoma, p53, PCNA
Full-Text  
Abstract   Immunohistochemical expression of the p53 was studied in 20 csses of benign proststic hypertrophy(BPH) and 56 prostatic adenocarcinomas using a monoclonal p53-specific DO7 anti- body (Novocastra, U.K.) on formaline-fixed paraffin-embedded tissue sections. Proliferative activity was determined by immunahistochemical detectian of proliferative cell nuclear antigen (PCNA) using a monoclonal PCIO antibody (Novocastra, U.K.). Eleven of 56 prostatic carcinomas(19.6%) showed strong immunostaining for p53 in more than 20% of tumor cells and 15 (28.6%) had focal(<=20%) immunoreactivity. The glandular epithelium adjacent to carcinomas showed features of prostatic intraepithelial neoplasia which was stained positively for p53 in 25%,but all cases of BPH showed no staining. High grade carcinomas(Gleasons combined score >=7) were associated with more intense and extensive p53 staining. High PCNA staining(higher than 50%)showed more p53 immunoreactivity(81.8%) than those cases with lower PCNA staining(40%). These findings indicste that altered expression of p53 protein occurs in a prostate cancer and is associated with increased proliferative activity and appears to play a role in the develpment of highly malignant prostatic carcinomas.
Àú ÀÚ   ±è±â±Ç(Ki Kwon Kim)